Sweden’s life sciences sector is world class — but to stay competitive, we must move faster. Products need to reach patients sooner, and our industry must increase its contribution to Sweden’s GDP. Looking east, Hong Kong offers a strategic gateway to make this happen.
Why Hong Kong?
- Gateway to Asia
Within a five-hour flight of half the world’s population, Hong Kong provides direct access to the Greater Bay Area — home to 80 million people and one of the world’s fastest-growing healthcare clusters. - Speed to Patients
Agile regulation and strong clinical networks allow Swedish companies to accelerate trials, approvals, and market entry — reducing time from innovation to impact. - Boosting GDP
By scaling into Asia, Swedish firms can expand exports, strengthen revenues, and drive the life sciences industry’s growing share of Sweden’s GDP. - Collaboration at Scale
Universities, hospitals, and investors in Hong Kong are actively seeking global partnerships, creating fertile ground for Swedish innovation.
Opportunities for Sweden
- Accelerated Clinical Trials & Approvals → Get treatments and technologies to patients faster.
- Export Growth → Expand into new markets and fuel Sweden’s GDP.
- Investor Access → Build connections with Asia-based venture capital and strategic investors.
- Innovation Partnerships → Co-develop with world-class research centres and hospitals.
The Case for Action
Sweden brings trusted quality, sustainability, and proven innovation. Hong Kong offers speed, scale, and access to Asia. Together, they form a powerful bridge where Swedish breakthroughs can reach patients faster — while fuelling growth for Sweden’s economy.
Going east isn’t just an opportunity. It’s a necessity for the future of Swedish life sciences.
👉 Interested in exploring opportunities in Hong Kong? Join us for the Nordic Life Science Delegation to Hong Kong, 10–12 December 2025.
